Qiming Venture Partners Wins 36Kr 2025 China Best ESG Investment Firm
ESG has become a powerful anchor for venture capital firms seeking certainty and reshaping value.
Recently, 36Kr released its 2025 "China Best ESG Investment Institutions" list. The survey reached out to hundreds of active investment institutions, comprehensively collecting their systematic thinking and innovative practices guided by ESG principles. Qiming Venture Partners was named to 36Kr's 2025 China Best ESG Investment Institutions.
Qiming Venture Partners
Awarded
2025 China Best ESG Investment Institution
Selection Criteria
The evaluation combined fundamental hard data (AUM, investment performance, exit track record) with six core dimensions of ESG practice (ESG management committee structure, specific applications of ESG principles in investment decision-making, post-investment ESG enablement of portfolio companies, commercial impact of representative ESG cases, ESG-related certifications held by the firm and its members, and other ESG-related philanthropic initiatives).
36Kr noted that as 2025 draws to a close, it marks a critical milestone for ESG development in China. ESG has become a powerful anchor for venture capital firms seeking certainty and reshaping value. With domestic ESG disclosure standards now fully implemented, investment institutions are evolving from former "gatekeepers" into "enablers," assisting portfolio companies in building data assets. Through continuous observation and positive enablement across the entire fundraising, investment, portfolio management, and exit cycle, they are laying a solid foundation for sustainable corporate development — ultimately translating into long-term, verifiable high-value returns.
Source | 36Kr
Past Coverage
Qiming ESG | Qiming Venture Partners Donates HK$3 Million to Tai Po Wang Fuk Court Relief Fund to Support Post-Disaster Reconstruction | Bilingual Qiming Perspectives | Qiming Venture Partners' Duane Kuang: Hong Kong Has Become a Critical International Financing Channel for Hard Tech Companies Qiming Honors | Qiming Venture Partners Wins Three Awards Including China Venture Capital Research Institute 2025 China Venture Capital Industry Annual Golden Investment Awards
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management of $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many of Qiming Venture Partners' portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Sinocelltech (688520.SH), Arbutus Biopharma, Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.